Co-transplantation of umbilical cord mesenchymal stem cells and peripheral blood stem cells in children and adolescents with refractory or relapsed severe aplastic anemia

References

• Yoshida N, Kojima S. Updated guidelines for the treatment of acquired aplastic anemia in children. Curr Oncol Rep. 2018;20(9):67. doi:10.1007/s11912-018-0716-8.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428–1436. doi:10.1182/blood-2016-08-693481.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Giammarco S, Sica S. Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. Int J Hematol. 2016;104(2):168–174. doi:10.1007/s12185-016-2037-8.
   PubMed Web of Science ®Google Scholar
• Georges GE, Doney K, Storb R. Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv. 2018;2(15):2020–2028. doi:10.1182/bloodadvances.2018021162.
   PubMed Web of Science ®Google Scholar
• Scheinberg P. Recent advances and long-term results of medical treatment of acquired aplastic anemia: are patients cured? Hematol Oncol Clin North Am. 2018;32(4):609–618. doi:10.1016/j.hoc.2018.03.003.
   PubMed Web of Science ®Google Scholar
• Ozdemir ZN, Civriz Bozdağ S. Graft failure after allogeneic hematopoietic stem cell transplantation. Transfus Apher Sci. 2018;57(2):163–167. doi:10.1016/j.transci.2018.04.014.
   PubMed Web of Science ®Google Scholar
• Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100(3):799–803. doi:10.1182/blood.v100.3.799.
   PubMed Web of Science ®Google Scholar
• Kobayashi R, Yabe H, Hara J, et al. Preceding immunosuppressive therapy with antithymocyte globulin and ciclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identical siblings. Br J Haematol. 2006;135(5):693–696. doi:10.1111/j.1365-2141.2006.06352.x.
   Web of Science ®Google Scholar
• Dufour C, Pillon M, Sociè G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169(4):565–573. doi:10.1111/bjh.13297.
   PubMed Web of Science ®Google Scholar
• Dufour C, Pillon M, Passweg J, et al. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014;99(10):1574–1581. doi:10.3324/haematol.2014.106096.
   PubMed Web of Science ®Google Scholar
• Perez-Albuerne ED, Eapen M, Klein J, et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol. 2008;141(2):216–223. doi:10.1111/j.1365-2141.2008.07030.x.
   Web of Science ®Google Scholar
• Szpecht D, Gorczyńska E, Kałwak K, et al. Matched sibling versus matched unrelated allogeneic hematopoietic stem cell transplantation in children with severe acquired aplastic anemia: experience of the polish pediatric group for hematopoietic stem cell transplantation. Arch Immunol Ther Exp. 2012;60(3):225–233. doi:10.1007/s00005-012-0174-1.
   Web of Science ®Google Scholar
• Salmi A, Holmström M, Toiviainen-Salo S, et al. Iron overload after allogeneic stem cell transplantation in children with acute lymphoblastic leukemia. Pediatr Transplant. 2020;24(8):e13846.
   PubMed Web of Science ®Google Scholar
• Zhao K, Liu Q. The clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantation. J Hematol Oncol. 2016;9(1):46. doi:10.1186/s13045-016-0276-z.
   PubMedGoogle Scholar
• Aqmasheh S, Shamsasanjan K, Akbarzadehlaleh P, et al. Effects of mesenchymal stem cell derivatives on hematopoiesis and hematopoietic stem cells. Adv Pharm Bull. 2017;7(2):165–177. doi:10.15171/apb.2017.021.
   Google Scholar
• Lin T, Yang Y, Chen X. A review of the application of mesenchymal stem cells in the field of hematopoietic stem cell transplantation. Eur J Med Res. 2023;28(1):268. doi:10.1186/s40001-023-01244-x.
   Web of Science ®Google Scholar
• Sacchetti B, Funari A, Remoli C, et al. No identical “mesenchymal stem cells” at different times and sites: human committed progenitors of distinct origin and differentiation potential are incorporated as adventitial cells in microvessels. Stem Cell Rep. 2016;6(6):897–913. doi:10.1016/j.stemcr.2016.05.011.
   PubMed Web of Science ®Google Scholar
• Gonzaga VF, Wenceslau CV, Lisboa GS, et al. Mesenchymal stem cell benefits observed in bone marrow failure and acquired aplastic anemia. Stem Cells Int. 2017;2017:8076529. doi:10.1155/2017/8076529.
   PubMed Web of Science ®Google Scholar
• Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48(1):63–70. doi:10.1182/blood.V48.1.63.63.
   PubMed Web of Science ®Google Scholar
• Schoemans HM, Lee SJ, Ferrara JL, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018;53(11):1401–1415. doi:10.1038/s41409-018-0204-7.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1. doi:10.1016/j.bbmt.2014.12.001.
   PubMed Web of Science ®Google Scholar
• Grube M, Holler E, Weber D, et al. Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study. Biol Blood Marrow Transplant. 2016;22(10):1781–1791. doi:10.1016/j.bbmt.2016.06.020.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36(11):947–950. doi:10.1038/sj.bmt.1705165.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Socie’ G, Lanino E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica. 2010;95(6):976–982. doi:10.3324/haematol.2009.018267.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, O'Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108(5):1485–1491. doi:10.1182/blood-2006-03-005041.
   PubMed Web of Science ®Google Scholar
• Meuleman N, Tondreau T, Ahmad I, et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells Dev. 2009;18(9):1247–1252. doi:10.1089/scd.2009.0029.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579–1586. doi:10.1016/S0140-6736(08)60690-X.
   PubMed Web of Science ®Google Scholar
• Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood. 2007;110(7):2764–2767. doi:10.1182/blood-2007-04-087056.
   PubMed Web of Science ®Google Scholar
• Fu Y, Wang Q, Zhou J, et al. Reduced intensity conditioning and co-transplantation of unrelated peripheral stem cells combined with umbilical cord mesenchymal stem/stroma cells for young patients with refractory severe aplastic anemia. Int J Hematol. 2013;98(6):658–663. doi:10.1007/s12185-013-1425-6.
   Web of Science ®Google Scholar
• Li T, Luo C, Zhang J, et al. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Stem Cell Res Ther. 2021;12(1):246. doi:10.1186/s13287-021-02304-x.
   PubMed Web of Science ®Google Scholar
• Sheng XF, Li H, Hong LL, et al. Combination of haploidentical hematopoietic stem cell transplantation with umbilical cord-derived mesenchymal stem cells in patients with severe aplastic anemia: a retrospective controlled study. Turk J Haematol. 2022;39(2):117–129.
   Web of Science ®Google Scholar
• Si Y, Yang K, Qin M, et al. Efficacy and safety of human umbilical cord derived mesenchymal stem cell therapy in children with severe aplastic anemia following allogeneic hematopoietic stem cell transplantation: a retrospective case series of 37 patients. Pediatr Hematol Oncol. 2014;31(1):39–49. doi:10.3109/08880018.2013.867556.
   PubMed Web of Science ®Google Scholar
• Akçay A, Atay D, Erbey F, et al. Safety and efficacy of co-transplantation of hematopoietic stem cells combined with human umbilical cord-derived mesenchymal stem cells in children with severe aplastic anemia: a single-center experience. Exp Clin Transplant. 2022;20(12):1114–1121. doi:10.6002/ect.2021.0027.
   Web of Science ®Google Scholar
• Yagasaki H, Takahashi Y, Hama A, et al. Comparison of matched-sibling donor BMT and unrelated donor BMT in children and adolescent with acquired severe aplastic anemia. Bone Marrow Transplant. 2010;45(10):1508–1513. doi:10.1038/bmt.2009.378.
   PubMed Web of Science ®Google Scholar
• Zhou J, Fu YW, Liang LJ, et al. [A comparative study of unrelated donor and matched-sibling donor allogeneic hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia]. Zhonghua Nei Ke Za Zhi. 2016;55(12):927–931.
   Google Scholar
• Wang S, Liu DB, Zheng XL, et al. [Clinical analysis of cytomegalovirus infection after different patterns of hematopoietic stem cell transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23(5):1438–1444.
   Google Scholar
• Cohen L, Yeshurun M, Shpilberg O, et al. Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation. Transpl Infect Dis. 2015;17(4):510–517. doi:10.1111/tid.12398.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78–83.
   PubMed Web of Science ®Google Scholar
• George B, Kerridge IH, Gilroy N, et al. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group. Transpl Infect Dis. 2012;14(2):141–148. doi:10.1111/j.1399-3062.2011.00706.x.
   Web of Science ®Google Scholar
• Moss P, Rickinson A. Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev Immunol. 2005;5(1):9–20. doi:10.1038/nri1526.
   PubMed Web of Science ®Google Scholar
• Bao X, Zhu Q, Qiu H, et al. [Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2016;37(2):138–143.
   Google Scholar
• Al Hamed R, Bazarbachi AH, Mohty M. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transplant. 2020;55(1):25–39. doi:10.1038/s41409-019-0548-7.
   Web of Science ®Google Scholar
• Kalra A, Roessner C, Jupp J, et al. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation. Clin Transplant. 2018;32(1):e13150.
   Web of Science ®Google Scholar
• Sundin M, Orvell C, Rasmusson I, et al. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant. 2006;37(11):1051–1059. doi:10.1038/sj.bmt.1705368.
   PubMed Web of Science ®Google Scholar
• Karlsson H, Samarasinghe S, Ball LM, et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood. 2008;112(3):532–541. doi:10.1182/blood-2007-10-119370.
   PubMed Web of Science ®Google Scholar
• Blennow O, Ljungman P, Sparrelid E, et al. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations. Transplant Infect Dis. 2014;16(1):106–114. doi:10.1111/tid.12175.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Del Bono V, Raiola AM, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant. 2009;15(1):47–53. doi:10.1016/j.bbmt.2008.10.024.
   PubMed Web of Science ®Google Scholar
• Choi J-K, Cho S-Y, Yoon S-S, et al. Epidemiology and risk factors for invasive fungal diseases among allogeneic hematopoietic stem cell transplant recipients in Korea: results of “RISK” study. Biol Blood Marrow Transplant. 2017;23(10):1773–1779. doi:10.1016/j.bbmt.2017.06.012.
   PubMed Web of Science ®Google Scholar
• Sun Y, Meng F, Han M, et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study. Biol Blood Marrow Transplant. 2015;21(6):1117–1126. doi:10.1016/j.bbmt.2015.03.018.
   PubMed Web of Science ®Google Scholar
• Yang SW, Ma RJ, Zhao JJ, et al. [Comparison of different styles of allogeneic hematopoietic stem cell transplantation as first-line treatment treated with severe aplastic anemia in children and adolescents]. Zhonghua Xue Ye Xue Za Zhi. 2018;39(3):184–189.
   Google Scholar